DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
First Investment: 2017
Genetically modifying cells — for example, to produce biologic drugs — is a costly, protracted, trial-and-error process because biology still lacks the design and modeling tools common in other engineering disciplines. Asimov offers a cloud-based computer-aided design platform for biology called Kernel that enables users to design and debug genetic systems; models like the Genetic Simulator that predict how those systems will behave; and standardized biological “parts,” such as customized Chinese hamster ovary that can produce specified antibodies and proteins. By integrating CAD, data-driven models, and synthetic biology tools, Asimov aims to provide drug designers with powerful abstractions for specifying a cell’s performance.
Explore Companies
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules
Visolis
Using synthetic biology to manufacture carbon-negative materials